AVI BioPharma announced confirmation from three independent laboratories of Neugene antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1. "Based on these recent findings and other results from additional studies, AVI now plans to file an Investigative New Drug (IND) application with the FDA," said Denis R Burger, Ph.D., CEO of AVI. Release